載入...
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S(®) coated modified release formulations of mesalamine, such as Asacol(®), remain among the most popular choices. We here review the current...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2009
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108647/ https://ncbi.nlm.nih.gov/pubmed/21694838 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|